Product Center
HRK-X®'s first landing in Macau
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-05
- Views:
(Summary description)Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
HRK-X®'s first landing in Macau
(Summary description)Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-05 09:03
- Views:
Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
The quadrivalent influenza virus subunit vaccine (HRK-X®) supplied to Macau this time adopts advanced third-generation influenza vaccine technology, which includes the main surface antigens of two types of influenza A and two types of influenza B viruses. It has the characteristics of high purity, good safety, and strong immunogenicity. Compared with traditional vaccines, this product further optimizes the process, significantly improves the safety and protective effect of vaccination, and is suitable for vaccination for various groups including high-risk populations.
On December 4th, the first dose of the vaccine was successfully administered at the Yin Kui Hospital in Macau. The event conveyed the concept of "active health and proactive prevention" to various sectors in Macau, and vividly demonstrated our company's corporate vision of "enabling China to use globally innovative vaccines and the world to use high-quality Chinese vaccines".
The business leader of the company stated in his speech, "We are very honored to bring this advanced subunit influenza vaccine to our compatriots in Macau. This cooperation is not only a breakthrough in market expansion, but also an important step for us to fulfill our corporate vision. We will continue to support Macau's public health cause and work together to safeguard the health of Macau residents.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
